Activating GP130 Pathway: A New Strategy Against Aggressive Prostate Cancer

A new study by an international research team led by MedUni Vienna unveils a promising strategy in **cancer treatment targeting the GP130 signalling pathway**. *Prostate cancer*, being the second most common cancer among men, remains a significant health burden. The study challenges previous assumptions by showing that activating, rather than inhibiting, the GP130 pathway results in reduced tumor growth and enhanced immune response against cancer cells. The research utilized genetically modified mice and examined tissue samples from prostate cancer patients, revealing that higher GP130 levels correlate with improved survival rates. These findings open a new therapeutic avenue, particularly beneficial for aggressive prostate cancers that are traditionally hard to treat. With further studies planned, this research marks a potential shift in cancer treatment paradigms.